Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neutral Protamine Hagedorn (NPH) insulin, also known as isophane insulin, is an intermediate-acting human insulin formulation used to manage blood glucose levels in patients with diabetes mellitus. It is produced by complexing recombinant human insulin with protamine and zinc, which delays its absorption and extends its duration of action to approximately 10–16 hours. In the context of the Assiut University study (NCT03835390), NPH is evaluated as part of a conventional insulin regimen in pregnant women with pre-gestational diabetes. The study compares this conventional approach against basal-bolus regimens using insulin analogues to determine the impact on maternal and fetal outcomes, such as glycemic control and the incidence of macrosomia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on neutral protamine hagedorn.